Neovascular growth factors

G. S. Schultz, M. B. Grant

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Neovascularisation is the biological process of forming new blood vessels. Many conditions can initiate neovascularisation including trauma or chronic ischaemia produced by diseases such as diabetes. Neovascularisation proceeds through a series of steps beginning with destruction of the basement membrane surrounding the microvascular endothelial cells, which allows endothelial cells to extend cytoplasmic buds in the direction of chemotactic factors. Migrating endothelial cells elongate, divide and eventually form tube structures which join to form mature new capillaries. Results of in vitro experiments, in vivo experiments, and clinical studies suggest that peptide growth factors can play key regulatory roles in each step of neovascularisation through both direct and indirect actions. At sites of vascular injuries, degranulating platelets release PDGF, IGF-I, EGF, and TGF-β. Macrophages and neutrophiles drawn into the ischaemic or injured areas synthesise and release TGF-α, TGF-β, and PDGF, and wounded endothelial cells secrete FGF. These peptide growth factors can stimulate migration, mitosis and differentiation of endothelial cells in culture and can induce neovascularisation in animal models. Clinical correlations suggest that peptide growth factors in the vitreous such as IGF-I and bFGF may promote diabetic retinopathy. As the biological mechanisms of neovascular growth factors become better understood, it may be possible to develop therapeutic approaches to selectively inhibit the peptide growth factors which regulate neovascular diseases.

Original languageEnglish (US)
Pages (from-to)170-180
Number of pages11
JournalEye (Basingstoke)
Volume5
Issue number2
StatePublished - 1991
Externally publishedYes

Fingerprint

Intercellular Signaling Peptides and Proteins
Endothelial Cells
Peptides
Insulin-Like Growth Factor I
Biological Phenomena
Vascular System Injuries
Chemotactic Factors
Diabetic Retinopathy
Mitosis
Epidermal Growth Factor
Basement Membrane
Blood Vessels
Neutrophils
Blood Platelets
Ischemia
Animal Models
Cell Culture Techniques
Macrophages
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Schultz, G. S., & Grant, M. B. (1991). Neovascular growth factors. Eye (Basingstoke), 5(2), 170-180.

Neovascular growth factors. / Schultz, G. S.; Grant, M. B.

In: Eye (Basingstoke), Vol. 5, No. 2, 1991, p. 170-180.

Research output: Contribution to journalArticle

Schultz, GS & Grant, MB 1991, 'Neovascular growth factors', Eye (Basingstoke), vol. 5, no. 2, pp. 170-180.
Schultz GS, Grant MB. Neovascular growth factors. Eye (Basingstoke). 1991;5(2):170-180.
Schultz, G. S. ; Grant, M. B. / Neovascular growth factors. In: Eye (Basingstoke). 1991 ; Vol. 5, No. 2. pp. 170-180.
@article{50ec0e90dcb0437687c6f404ad92d624,
title = "Neovascular growth factors",
abstract = "Neovascularisation is the biological process of forming new blood vessels. Many conditions can initiate neovascularisation including trauma or chronic ischaemia produced by diseases such as diabetes. Neovascularisation proceeds through a series of steps beginning with destruction of the basement membrane surrounding the microvascular endothelial cells, which allows endothelial cells to extend cytoplasmic buds in the direction of chemotactic factors. Migrating endothelial cells elongate, divide and eventually form tube structures which join to form mature new capillaries. Results of in vitro experiments, in vivo experiments, and clinical studies suggest that peptide growth factors can play key regulatory roles in each step of neovascularisation through both direct and indirect actions. At sites of vascular injuries, degranulating platelets release PDGF, IGF-I, EGF, and TGF-β. Macrophages and neutrophiles drawn into the ischaemic or injured areas synthesise and release TGF-α, TGF-β, and PDGF, and wounded endothelial cells secrete FGF. These peptide growth factors can stimulate migration, mitosis and differentiation of endothelial cells in culture and can induce neovascularisation in animal models. Clinical correlations suggest that peptide growth factors in the vitreous such as IGF-I and bFGF may promote diabetic retinopathy. As the biological mechanisms of neovascular growth factors become better understood, it may be possible to develop therapeutic approaches to selectively inhibit the peptide growth factors which regulate neovascular diseases.",
author = "Schultz, {G. S.} and Grant, {M. B.}",
year = "1991",
language = "English (US)",
volume = "5",
pages = "170--180",
journal = "Eye",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Neovascular growth factors

AU - Schultz, G. S.

AU - Grant, M. B.

PY - 1991

Y1 - 1991

N2 - Neovascularisation is the biological process of forming new blood vessels. Many conditions can initiate neovascularisation including trauma or chronic ischaemia produced by diseases such as diabetes. Neovascularisation proceeds through a series of steps beginning with destruction of the basement membrane surrounding the microvascular endothelial cells, which allows endothelial cells to extend cytoplasmic buds in the direction of chemotactic factors. Migrating endothelial cells elongate, divide and eventually form tube structures which join to form mature new capillaries. Results of in vitro experiments, in vivo experiments, and clinical studies suggest that peptide growth factors can play key regulatory roles in each step of neovascularisation through both direct and indirect actions. At sites of vascular injuries, degranulating platelets release PDGF, IGF-I, EGF, and TGF-β. Macrophages and neutrophiles drawn into the ischaemic or injured areas synthesise and release TGF-α, TGF-β, and PDGF, and wounded endothelial cells secrete FGF. These peptide growth factors can stimulate migration, mitosis and differentiation of endothelial cells in culture and can induce neovascularisation in animal models. Clinical correlations suggest that peptide growth factors in the vitreous such as IGF-I and bFGF may promote diabetic retinopathy. As the biological mechanisms of neovascular growth factors become better understood, it may be possible to develop therapeutic approaches to selectively inhibit the peptide growth factors which regulate neovascular diseases.

AB - Neovascularisation is the biological process of forming new blood vessels. Many conditions can initiate neovascularisation including trauma or chronic ischaemia produced by diseases such as diabetes. Neovascularisation proceeds through a series of steps beginning with destruction of the basement membrane surrounding the microvascular endothelial cells, which allows endothelial cells to extend cytoplasmic buds in the direction of chemotactic factors. Migrating endothelial cells elongate, divide and eventually form tube structures which join to form mature new capillaries. Results of in vitro experiments, in vivo experiments, and clinical studies suggest that peptide growth factors can play key regulatory roles in each step of neovascularisation through both direct and indirect actions. At sites of vascular injuries, degranulating platelets release PDGF, IGF-I, EGF, and TGF-β. Macrophages and neutrophiles drawn into the ischaemic or injured areas synthesise and release TGF-α, TGF-β, and PDGF, and wounded endothelial cells secrete FGF. These peptide growth factors can stimulate migration, mitosis and differentiation of endothelial cells in culture and can induce neovascularisation in animal models. Clinical correlations suggest that peptide growth factors in the vitreous such as IGF-I and bFGF may promote diabetic retinopathy. As the biological mechanisms of neovascular growth factors become better understood, it may be possible to develop therapeutic approaches to selectively inhibit the peptide growth factors which regulate neovascular diseases.

UR - http://www.scopus.com/inward/record.url?scp=0026056194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026056194&partnerID=8YFLogxK

M3 - Article

C2 - 1712736

AN - SCOPUS:0026056194

VL - 5

SP - 170

EP - 180

JO - Eye

JF - Eye

SN - 0950-222X

IS - 2

ER -